Lyell Immunopharma (LYEL) news

Lyell Immunopharma Q2 operating income USD -47.337 million

Lyell Immunopharma Q2 operating expenses USD 47.341 million

Lyell Immunopharma, Inc.: Stifel initiates coverage with buy rating; target price $36

Stifel has initiated coverage on Lyell Immunopharma (NASDAQ: LYEL) with a "Buy" rating and a price target of $36.00, representing potential upside of approximately 180% from the current stock price of $13.45. The firm highlighted the company’s dual-targeting CD19/CD20 autologous CAR T-cell therapy,…

Lyell Immunopharma - to offer up to 1.1 mln common shares by selling stockholder - SEC filing

Lyell Immunopharma, Inc. (Nasdaq: LYEL) has filed with the U.S. Securities and Exchange Commission (SEC) to register the resale of up to 1.1 million shares of its common stock by selling stockholders. The shares are being offered by existing stockholders and will not result in any proceeds to…

Lyell: end-of-phase 1 meeting with FDA expected in second half

Lyell Immunopharma, Inc. (Nasdaq: LYEL) is preparing for an End of Phase 1 (EOP1) meeting with the U.S. Food and Drug Administration (FDA) in the second half of 2026, as part of its ongoing clinical development of rondecabtagene autoleucel (ronde-cel), a next-generation dual-targeting CAR T-cell…